Polymorphic analysis of CYP2C9 gene in Vietnamese population

[1]  L. Kang,et al.  Genetic polymorphisms analysis of drug-metabolizing enzyme CYP2C9 in the Uyghur population , 2016, Xenobiotica; the fate of foreign compounds in biological systems.

[2]  Kyoko Iwao-Koizumi,et al.  Combination Analysis in Genetic Polymorphisms of Drug-Metabolizing Enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese Population , 2015, International journal of medical sciences.

[3]  T. Rusdiana,et al.  Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population , 2013, European Journal of Clinical Pharmacology.

[4]  R. Ge,et al.  CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database , 2013, The Pharmacogenomics Journal.

[5]  R. Saxena,et al.  Variability in CYP2C9 allele frequency: A pilot study of its predicted impact on warfarin response among healthy South and North Indians , 2013, Pharmacological reports : PR.

[6]  I. Adzhubei,et al.  Predicting Functional Effect of Human Missense Mutations Using PolyPhen‐2 , 2013, Current protocols in human genetics.

[7]  C. Jang,et al.  Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics , 2011, Acta Pharmacologica Sinica.

[8]  V. Kristensen,et al.  Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations , 2010, European Journal of Clinical Pharmacology.

[9]  R. Desnick,et al.  Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. , 2010, Pharmacogenomics.

[10]  L. Teh,et al.  CYP2C9 polymorphism: prevalence in healthy and warfarin-treated Malay and Chinese in Malaysia. , 2009, Singapore medical journal.

[11]  N. Tajik,et al.  GENETIC POLYMORPHISMS OF CYTOCHROME P450 ENZYMES 2C9 AND 2C19 IN A HEALTHY IRANIAN POPULATION , 2007, Clinical and experimental pharmacology & physiology.

[12]  S. Henikoff,et al.  Predicting the effects of amino acid substitutions on protein function. , 2006, Annual review of genomics and human genetics.

[13]  K. Kim,et al.  Genetic Polymorphism of CYP2C9 in a Vietnamese Kinh Population , 2005, Therapeutic drug monitoring.

[14]  A. Caputi,et al.  Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. , 2004, Pharmacological research.

[15]  J. Brockmöller,et al.  Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. , 1999, British journal of clinical pharmacology.

[16]  S D Hall,et al.  Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. , 1997, Biochemical pharmacology.

[17]  D. Shen,et al.  Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[18]  S. Wrighton,et al.  Role of cytochrome P450 2C9 and an allelic variant in the 4'-hydroxylation of (R)- and (S)-flurbiprofen. , 1995, Biochemical pharmacology.

[19]  P. Chakravarty,et al.  Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[20]  Yoshiro Saito,et al.  Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. , 2012, Drug metabolism and pharmacokinetics.

[21]  T. Aoyama,et al.  Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. , 1992, Chemical research in toxicology.

[22]  J. Momeni.  The population of Iran : a dynamic analysis = [Jamʿīyat-i Īrān] , 1975 .